{
    "biomarker_id": "AN6476-1",
    "biomarker_canonical_id": "AN6476",
    "condition": {
        "recommended_name": {
            "id": "DOID:1324",
            "resource": "Disease Ontology",
            "url": "https://disease-ontology.org/term/DOID:1324",
            "name": "lung cancer",
            "description": "A respiratory system cancer that is located_in the lung."
        },
        "synonyms": [
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer",
                "description": "A malignant neoplasm involving the lung."
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "adenocarcinoma of lung, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "adenocarcinoma of lung, somatic",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "cancer of lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer, protection against, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer, resistance to, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer, somatic",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer, susceptibility to, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant lung neoplasm",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant lung tumor",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant lung tumour",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant neoplasm of lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant neoplasm of the lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant tumor of lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant tumor of the lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant tumour of lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant tumour of the lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "nonsmall cell lung cancer, somatic",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "nonsmall cell lung cancer, susceptibility to, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0012159",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012159",
                "name": "lung cancer susceptibility 1",
                "description": ""
            },
            {
                "id": "MONDO:0012159",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012159",
                "name": "LNCR1",
                "description": ""
            },
            {
                "id": "MONDO:0012159",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012159",
                "name": "lung cancer susceptibility",
                "description": ""
            },
            {
                "id": "MONDO:0012159",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012159",
                "name": "lung cancer susceptibility 1",
                "description": ""
            },
            {
                "id": "MONDO:0012942",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012942",
                "name": "lung cancer susceptibility 3",
                "description": ""
            },
            {
                "id": "MONDO:0012942",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012942",
                "name": "LNCR3",
                "description": ""
            },
            {
                "id": "MONDO:0012942",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012942",
                "name": "lung cancer susceptibility 3",
                "description": ""
            },
            {
                "id": "MONDO:0012955",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012955",
                "name": "lung cancer susceptibility 4",
                "description": ""
            },
            {
                "id": "MONDO:0012955",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012955",
                "name": "LNCR4",
                "description": ""
            },
            {
                "id": "MONDO:0012955",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012955",
                "name": "lung cancer susceptibility 4",
                "description": ""
            },
            {
                "id": "MONDO:0013631",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0013631",
                "name": "lung cancer susceptibility 5",
                "description": ""
            },
            {
                "id": "MONDO:0013631",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0013631",
                "name": "LNCR5",
                "description": ""
            },
            {
                "id": "MONDO:0013631",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0013631",
                "name": "lung cancer susceptibility 5",
                "description": ""
            },
            {
                "id": "MIM:211980",
                "resource": "MIM",
                "url": "https://www.omim.org/entry/211980",
                "name": "Lung cancer",
                "description": "Lung cancer"
            }
        ],
        "id": "DOID:1324"
    },
    "biomarker_component": [
        {
            "biomarker": "increased HP level",
            "assessed_biomarker_entity_id": "P00738-1",
            "assessed_entity_type": "protein",
            "assessed_biomarker_entity": {
                "recommended_name": "Haptoglobin",
                "synonyms": [
                    {
                        "synonym": "Zonulin"
                    }
                ]
            },
            "specimen": [
                {
                    "name": "blood",
                    "namespace": "UBERON",
                    "id": "0000178",
                    "url": "http://purl.obolibrary.org/obo/UBERON_0000178",
                    "loinc_code": "4542-7"
                }
            ],
            "evidence_source": [
                {
                    "id": "AN6476-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6476-1"
                },
                {
                    "id": "27648369",
                    "database": "PubMed",
                    "url": "https://glygen.org/publication/PubMed/27648369",
                    "tags": [
                        "assessed_biomarker_entity",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "HP may be a potential serological biomarker for lung adenocarcinoma diagnostics, especially in male subjects. We found that HP levels were significantly higher and APOA1 levels were significantly lower in lung cancer patients. However, after the participants were stratified by gender, the expression trends of HP and APOA1 in lung cancer patients existed only in men, which is gender specific phenomenon. HP, APOA1 and carcinoembryonic antigen (CEA), used for distinguishing lung adenocarcinoma, had a sensitivity of 64%, 64% and 79%, respectively. Area under the ROC curve (AUC) of HP, APOA1 and CEA were 0.768, 0.761 and 0.884, respectively. When restricted to male subjects, HP, APOA1 and CEA showed sensitivity of 89%, 73% and 100%, respectively. AUC of HP, APOA1 and CEA were 0.929, 0.840 and 0.877, respectively."
                        }
                    ]
                }
            ]
        }
    ],
    "best_biomarker_role": [
        {
            "role": "diagnostic"
        }
    ],
    "evidence_source": [
        {
            "id": "AN6476-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/AN6476-1"
        },
        {
            "id": "27648369",
            "database": "PubMed",
            "url": "https://glygen.org/publication/PubMed/27648369",
            "tags": [
                "best_biomarker_role",
                " condition"
            ],
            "evidence_list": [
                {
                    "evidence": "HP may be a potential serological biomarker for lung adenocarcinoma diagnostics, especially in male subjects. We found that HP levels were significantly higher and APOA1 levels were significantly lower in lung cancer patients. However, after the participants were stratified by gender, the expression trends of HP and APOA1 in lung cancer patients existed only in men, which is gender specific phenomenon. HP, APOA1 and carcinoembryonic antigen (CEA), used for distinguishing lung adenocarcinoma, had a sensitivity of 64%, 64% and 79%, respectively. Area under the ROC curve (AUC) of HP, APOA1 and CEA were 0.768, 0.761 and 0.884, respectively. When restricted to male subjects, HP, APOA1 and CEA showed sensitivity of 89%, 73% and 100%, respectively. AUC of HP, APOA1 and CEA were 0.929, 0.840 and 0.877, respectively."
                }
            ]
        }
    ],
    "crossref": [
        {
            "id": "AN6476-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/AN6476-1",
            "categories": [
                "Biomarkers"
            ]
        }
    ],
    "citation": [
        {
            "title": "Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry.",
            "journal": "American journal of cancer research",
            "authors": "Chang YK, Lai YH, Chu Y, Lee MC, Huang CY, Wu S",
            "date": "2016",
            "reference": [
                {
                    "type": "PubMed",
                    "id": "27648369",
                    "url": "https://glygen.org/publication/PubMed/27648369"
                }
            ],
            "evidence": [
                {
                    "id": "AN6760-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6476-1"
                }
            ]
        }
    ],
    "section_stats": [
        {
            "table_id": "biomarker_component",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "biomarker",
                "assessed_biomarker_entity_id",
                "assessed_entity_type",
                "assessed_biomarker_entity.recommended_name"
            ]
        },
        {
            "table_id": "citation",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "title",
                "journal",
                "authors",
                "date"
            ]
        }
    ]
}